



ELUVIA[™] Drug-Eluting Vascular Stent System

Pushing patency beyond bare-metal and drug-coated stents



12-Month Target Lesion Revascularization (TLR) Rate




Results from different trials are not directly comparable. Information provided for educational purposes.


- 1. Data obtained from product SSED found on www.fda.com on 7Dec2015. Primary patency defined as a binary duplex ultrasound ratio < 2.4 at the stented target lesion with no clinically-driven reintervention without the stented segment. n=287
- 2. Data obtained from product SSED found on www.fda.com on 7Dec2015. Primary patency defined as PSV ratio of ≤ 2.4. n=264
- 3. Laird J, et al. Circ Cardiovasc Intervention. 2010;3:267-276. Primary patency defined as PSVR ≥ 2.5. n=206

4. Kaplan-Meier estimate of 12-month primary patency. Data obtained from product SSED found on www.fda.com on 7Dec2015. Primary patency defined as PSV ratio of < 2.0. n=47

The Challenge: A Harsh SFA Environment



Significant mechanical forces in the SFA prolong the response to injury and make the SFA susceptible to restenosis.




The Solution: Sustained Drug Release

The Eluvia[™] Stent, with Sustend[™] drug-delivery technology, is designed to deliver paclitaxel when restenosis is most likely to occur.

Polymer-based technology with proven biocompatibility¹

- Implanted in more than 10 million vessels since 2007
- More than 20,000 patients studied in clinical trials



Based on pre-clinical PK analysis. Data on file at Boston Scientific. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.

Built on the Innova[™] Stent platform, designed to optimize:

- Flexibility
- Radial strength
- Fracture resistance

While providing uniform scaffolding for drug delivery.


The Outcome: **UNPRECEDENTED** Results in the SFA


MAJESTIC CLINICAL TRIAL

TRIAL OVERVIEW

- Core lab adjudicated single-arm, multicenter trial (n=57)
- 65% of lesions severely calcified
- 46% total occlusions
- 71 mm average lesion length


12-MONTH RESULTS





ELUVIA[™] Drug Eluting Vascular Stent System

Triaxial delivery system for more precise and predictable stent placement



CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, , warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. This material is not for use or distribution in France. Eluvia is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are property of their respective owners.



Advancing science for life^{**} www.bostonscientific.eu